Navigation Links
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
Date:1/14/2014

onjugate technology platform; and the potential of certain of our other drug candidates and those of our collaboration partners. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, observations and assumptions regarding the potential of our business, drug candidates, and our technology. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) the statements regarding the therapeutic potential of NKTR-171 are based on preclinical data only and data from clinical studies may not confirm these potential therapeutic benefits; (ii) NKTR-171 is in early stage clinical development and could fail at any time due to numerous unpredictable and significant risks related to safety, efficacy and other important findings that can negatively impact clinical development; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates such as NKTR-171 is therefore very uncertain and unpredictable and could unexpectedly fail at any time; (iv) patents may not issue from our patent applications for NKTR-171 or additional intellectual property licenses from third parties may be required; and (v) the outcome of any potential intellectual property or other litigation related to our proprietary drug candidates.  Other important risks and uncertainties are detailed in our
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
2. 2014 Beauty Breakthrough -- Age-Defying Laser brings professional, anti-aging treatments into the home for the first time
3. QIAGEN and Exosome Diagnostics to Develop First-In-Class, Non-Invasive Diagnostics for Key Genetic Biomarkers in Lung and Other Cancers
4. Hill-Rom Holdings, Inc. Hosts Fiscal 2014 First Quarter Earnings Conference Call and Webcast
5. Xlumena Announces Initial Commercial Use of its First-in-Class AXIOS Stent and Delivery System for Treatment of Pancreatic Pseudocysts and Fluid Collections
6. Hologic to Release First Quarter Fiscal 2014 Operating Results on Monday, February 3, 2014
7. Philips receives FDA clearance for First-Ever Spectral Breast Density Measurement Application
8. Harrisburg-based Cardiovascular Institute Performs First MitraClip Procedure in Pennsylvania
9. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
10. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
11. Lilly Declares First-Quarter 2014 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas , Nov. 21, 2014  World Hemp ... containing low THC, announces they are now offering legal, ... to Charlotte,s Web type strains grown in medical marijuana ... other neurological disorders, such as Parkinson,s, MS, and spinal ... US laws to pass, because imported CBD Oil Is ...
(Date:11/21/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... to acquire 100% of QCR & Trio Diagnostics Limited, ... organization. The transaction closed on November 17, 2014. ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, ... dass die Europäische Arzneimittel-Agentur (European Medicines ... Orphan-Medizinprodukt an Palovarotene vergeben hat, den ... von Fibrodysplasia ossificans progressiva (FOP). FOP ... Krankheit, die von schmerzhaften, wiederkehrenden Episoden ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... , , LINCOLNSHIRE, Ill. ... leading specialty distributor of health care products in the emergency ... has acquired CVC, Inc.  Headquartered in Arlington, Texas , ... respiratory and emergency medical services markets.   , The privately ...
... , Jan. 12 Stereotaxis (Nasdaq: ... has been approved by the U.S. Food and Drug ... the treatment of Type 1 atrial flutter.  The product ... on-going co-development agreement between Stereotaxis and Biosense Webster to ...
Cached Medicine Technology:Sarnova Announces Acquisition of CVC, Inc. to Expand Portfolio of Specialty Medical Products 2Sarnova Announces Acquisition of CVC, Inc. to Expand Portfolio of Specialty Medical Products 3Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter 2Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter 3
(Date:11/24/2014)... 2014 Volpara Solutions announced today ... the 100th Annual Meeting of the Radiology Society ... (RSNA Booth 1752 – South Hall). Volpara Solutions ... the rest of its innovative suite of quantitative ... enable personalized measurements of volumetric density, patient-specific dose, ...
(Date:11/24/2014)... SweetDressy.com, a well-known dress supplier and leader in the ... Dresses. All these fresh items are offered at affordable ... special offer is valid until Dec. 20, 2014. Click ... working well in the fashion industry for years. They ... dresses may be the best products for many ladies ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis Global ... the Aspergillosis clinical trial scenario. This report provides ... trials on Aspergillosis. It includes an overview of ... per the site of trial conduction across the ... disease clinical trials by their phase, trial status, ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... Paramount Acquisition,Corp. (OTC Bulletin Board: PMQC, PMQCU, ... the filing of a third,amendment to the preliminary ... that was originally filed on June 18, 2007. ... meeting of,stockholders to be held to consider the ...
... Rendell,recently appointed Richard Snyder, M.D., senior vice president ... the state,s Chronic Care,Commission. Snyder took his oath ... other commission appointees during its first meeting. ... for Pennsylvanians,living with chronic health conditions such as ...
... Barcelona, Spain: One of the largest individual studies of the ... concluded that it makes no difference whether a woman drinks ... itself (ethyl alcohol) and the quantity consumed that is likely ... risk from drinking three or more alcoholic drinks a day ...
... A new study adds fuel to the debate over whether ... cancer. , The study, presented by Australian ... in Barcelona, found some evidence suggesting exercise might increase the ... study included 24,479 Australian women aged between 27 and 75, ...
... 27 Sagent Pharmaceuticals,Inc., a privately-held specialty ... $53 million Series A financing led by ... used primarily to fund near-term product,launches, product ... development, sales and marketing,manufacturing and distribution partnerships. ...
... Pa., Sept. 26 Kensey Nash Corporation,(Nasdaq: ... Ramius Capital Group,L.L.C. and its affiliates on August ... the,Company,s outstanding common stock, as reported by Ramius ... Control" under the Company,s equity,compensation plan. As a ...
Cached Medicine News:Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 4Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 3Health News:Wine, women and... spirits, beer and breast cancer risk 2Health News:Wine, women and... spirits, beer and breast cancer risk 3Health News:Study fuels debate over whether exercise and body size influence ovarian cancer risk 2Health News:Study fuels debate over whether exercise and body size influence ovarian cancer risk 3Health News:Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing 2Health News:Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares 2Health News:Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares 3Health News:Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares 4
... PDCs computer-generated Thermal Printing Wristbands and ... direct thermal and thermal transfer printers. ... activate a heat-sensitive thermal coating under ... printers use heat to transfer highly ...
... Wristbands and Tags print in mere ... transfer printers. Direct thermal printers use ... coating under the bands protective surface. ... transfer highly durable ink from a ...
... coded patient identification bracelets (wristbands) and/or ... at patient care areas throughout the ... identification and in creating a positive ... back to the patient through the ...
... secure band is desired for adults and where an ... appropriate. The design allows for two bands to be ... on the wrist and the second to be held ... This is particularly useful in a hospital situation wherea ...
Medicine Products: